Peptides
RT
Also known as Retatrutide, Retatrutide 15mg, Retatrutide 30mg, Retatrutide 60mg, RT, RT 15, RT 30, RT 60
- Research classification
- Peptides
For laboratory research use only. Not for human or veterinary use.
Lot & quality
Lot-specific analytical documentation
No verified lot documentation is published for this compound yet. Results, laboratories and purity values are never shown without a source record for the exact lot.
View available lot-specific analytical documentationEnter lot number
Verification connects to the BioNex lot and COA records in a later phase — no results are returned yet
- 01
Lot Number
- 02
COA
- 03
HPLC
- 04
Mass Spectrometry
- 05
Purity
- 06
Laboratory
- 07
Testing Date
- 08
QR Verification
Research snapshot
Verified research records currently indexed by BioNex
- Publication records
- 66
- Registered clinical trials
- 8
- Human interventional
- 9
- Preclinical
- 1
- Reviews
- 16
- International records
- 2
- Years indexed
- 2022–2026
Categories are listed separately and must not be added together: publication records and registered trial records are different record types, and a single study may appear in more than one category.
Compound profile
Research overview
Curated research content has not yet been imported for this compound. No generated summary is shown in its place.
Classification
Research areas
- Metabolic Signaling
Targets
Mechanisms under investigation
Combined GIP, GLP-1 and glucagon receptor agonism
Established target
Retatrutide (LY3437943) is reported in peer-reviewed phase 2 publications as an agonist at the GIP, GLP-1 and glucagon receptors. Clinical development is ongoing; no marketing authorisation exists.
Source
Evidence
Evidence breakdown
Direct compound evidence
65
Publication records indexed as describing this compound directly.
Related evidence
0
Parent-molecule or fragment literature. Counted separately and never added to direct evidence.
Human research
- Human interventional9
Records describing research in human participants.
Preclinical research
- Animal1
Animal and laboratory records. Not human evidence.
Review literature
- Reviews16
Reviews summarise other work rather than reporting new results.
Registered clinical trials
- Registered trial records8
Registration records a study, not a result. Trials are counted separately from publications.
Scientific identity
Compound identity
- Canonical scientific name
- Retatrutide (LY3437943)
- Alternate names
- Retatrutide, Retatrutide 15mg, Retatrutide 30mg, Retatrutide 60mg, RT, RT 15, RT 30, RT 60
- Research classification
- Peptides
Indexed literature describes: No chemistry fields assigned.
These records describe the scientific entity reported in the literature. Lot-specific analytical documentation is available through BioNex Quality Verification when provided for the applicable lot.
Scientific data
- Compound
- RT
- Alternate names
- Retatrutide, Retatrutide 15mg, Retatrutide 30mg, Retatrutide 60mg, RT, RT 15, RT 30, RT 60
- Research classification
- Peptides
Global research
Research records by jurisdiction
Jurisdictions appear only where an indexed record establishes them. Research recorded in one country never implies authorisation in another.
Loading United States records
Published research
Representative recent records
Verified records currently indexed by BioNex
Loading records
Regulatory
Regulatory records by jurisdiction
Regulatory records are held separately from research evidence. Authorisation or regulatory activity in one jurisdiction never implies the same status in another.
FDA safety communication on compounded and illegally marketed semaglutide products
U.S. Food and Drug Administration (FDA) · FDA postmarket drug safety communication regarding compounded and illegally marketed semaglutide products. Not an approval action for BioNex material and not an efficacy judgement. · 2026-05-31
Not an approval determination
Primary source
Scientific identity records describe the entity reported in the literature. Lot-specific analytical documentation is available through BioNex Quality Verification when provided for the applicable lot.
BioNex Research Intelligence summarizes and organizes scientific literature for research and educational purposes. Inclusion of a publication, clinical trial, or regulatory record does not constitute endorsement, clinical guidance, or evidence of safety or efficacy for human use.
Related
